Recent 24-month HOPE-3 data, now included in the regulatory submission, offer longer-term evidence supporting deramiocel, which is significant as the FDA reviews the drug’s benefit-risk profile despite lingering uncertainties from the advisory committee.
Capricor jumps as study shows longer-term effects of deramiocel (CAPR:NASDAQ)
